Skip to main content
logo
Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
5.04
-0.14 (-2.70%)
Jul 30, 2026, 1:45 PM CST

Merdury Biopharmaceutical Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--4.961.032.68-
Revenue Growth
--380.44%-61.46%--
Gross Profit
--4.180.591.17-
Operating Income
-68.55-68.55-54.04-45.69-30.9-5.3
Net Income
-67.23-67.23-50.57-43.82-31.25-5.31
Earnings Per Share
-0.16-0.16-0.12-0.11-0.08-0.02
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
163.77163.77230.81329.07140.642.56
Total Debt
41.7941.7947.5142.3543.422.01
Net Cash (Debt)
121.98121.98183.3286.7397.210.55
Net Cash Growth
-19.78%-33.45%-36.07%194.94%17575.09%-
Net Cash Per Share
0.290.290.440.720.260.00

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-50.84-50.84-34.71-42.15-25.84-4.78
Capital Expenditures
-6.88-6.88-10.02-12.93-68.51-6.98
Free Cash Flow
-57.72-57.72-44.73-55.07-94.35-11.77
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--84.30%57.31%43.73%-
Operating Margin
---1088.90%-4423.04%-1152.91%-
Pretax Margin
---1018.09%-4241.63%-1166.04%-
Profit Margin
---1018.90%-4241.63%-1166.05%-
FCF Margin
---901.17%-5331.17%-3520.60%-

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
--1107.827530.001494.92-